These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7697342)

  • 21. Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A.
    Fuxe J; Akusjärvi G; Goike HM; Roos G; Collins VP; Pettersson RF
    Cell Growth Differ; 2000 Jul; 11(7):373-84. PubMed ID: 10939591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
    Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
    Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor-suppressor genes. Open questions on p16.
    Bonetta L
    Nature; 1994 Jul; 370(6486):180. PubMed ID: 8028659
    [No Abstract]   [Full Text] [Related]  

  • 24. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
    Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
    Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell division cycle alterations and human tumors.
    Della Ragione F; Borriello A; Della Pietra V; Cucciolla V; Oliva A; Barbarisi A; Iolascon A; Zappia V
    Adv Exp Med Biol; 1999; 472():73-88. PubMed ID: 10736618
    [No Abstract]   [Full Text] [Related]  

  • 26. Coincidental alterations of p16INK4A/CDKN2 and other genes in human lung cancer cell lines.
    Fujishita T; Mizushima Y; Kashii T; Kobayashi M
    Anticancer Res; 1998; 18(3A):1537-42. PubMed ID: 9673367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A cell cycle regulator potentially involved in genesis of many tumor types.
    Kamb A; Gruis NA; Weaver-Feldhaus J; Liu Q; Harshman K; Tavtigian SV; Stockert E; Day RS; Johnson BE; Skolnick MH
    Science; 1994 Apr; 264(5157):436-40. PubMed ID: 8153634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Homozygous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma.
    Sonoda Y; Yoshimoto T; Sekiya T
    Oncogene; 1995 Nov; 11(10):2145-9. PubMed ID: 7478535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutational analysis of the p16 family cyclin-dependent kinase inhibitors p15INK4b and p18INK4c in tumor-derived cell lines and primary tumors.
    Zariwala M; Liu E; Xiong Y
    Oncogene; 1996 Jan; 12(2):451-5. PubMed ID: 8570224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assignment of the cyclin-dependent kinase inhibitor genes Cdkn2a and Cdkn2b to rat chromosome bands 5q32-->q34 and 5q31-->q33, respectively by fluorescence in situ hybridization, using small PCR-generated probes.
    Laes JF; Van Vooren P; Szpirer J; Szpirer C
    Cytogenet Cell Genet; 1998; 81(3-4):290-1. PubMed ID: 9730623
    [No Abstract]   [Full Text] [Related]  

  • 31. Cooperative alterations of Rb pathway regulators in mouse primary T cell lymphomas.
    Pérez de Castro IP; Malumbres M; Santos J; Pellicer A; Fernández-Piqueras J
    Carcinogenesis; 1999 Sep; 20(9):1675-82. PubMed ID: 10469610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The CDKN2A (p16) gene and human cancer.
    Foulkes WD; Flanders TY; Pollock PM; Hayward NK
    Mol Med; 1997 Jan; 3(1):5-20. PubMed ID: 9132280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas.
    Maelandsmo GM; Flørenes VA; Hovig E; Oyjord T; Engebraaten O; Holm R; Børresen AL; Fodstad O
    Br J Cancer; 1996 Apr; 73(8):909-16. PubMed ID: 8611425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitors of mammalian G1 cyclin-dependent kinases.
    Sherr CJ; Roberts JM
    Genes Dev; 1995 May; 9(10):1149-63. PubMed ID: 7758941
    [No Abstract]   [Full Text] [Related]  

  • 35. Biochemical and mutagenic analysis of the melanoma tumor suppressor gene product/p16.
    Wick ST; Dubay MM; Imanil I; Brizuela L
    Oncogene; 1995 Nov; 11(10):2013-9. PubMed ID: 7478520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of tumor suppressor genes in the development of adult T cell leukemia/lymphoma (ATLL).
    Hatta Y; Koeffler HP
    Leukemia; 2002 Jun; 16(6):1069-85. PubMed ID: 12040438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Loss of heterozygosity on chromosome 9 and p16 (MTS1, CDKN2) gene mutations in esophageal cancers.
    Muzeau F; Fléjou JF; Thomas G; Hamelin R
    Int J Cancer; 1997 Jul; 72(1):27-30. PubMed ID: 9212218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. P16Ink4a tumor suppressor function in lung cancer cells involves cyclin-dependent kinase 2 inhibition by Cip/Kip protein redistribution.
    Grimison B; Langan TA; Sclafani RA
    Cell Growth Differ; 2000 Oct; 11(10):507-15. PubMed ID: 11063124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rates of p16 (MTS1) mutations in primary tumors with 9p loss.
    Cairns P; Mao L; Merlo A; Lee DJ; Schwab D; Eby Y; Tokino K; van der Riet P; Blaugrund JE; Sidransky D
    Science; 1994 Jul; 265(5170):415-7. PubMed ID: 8023167
    [No Abstract]   [Full Text] [Related]  

  • 40. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer.
    Tsihlias J; Kapusta L; Slingerland J
    Annu Rev Med; 1999; 50():401-23. PubMed ID: 10073286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.